HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ADW 742

an antineoplastic agent that inhibits insulin-like growth factor 1 receptor kinase

Also Known As:

ADW-742; ADW742

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - ADW 742: 1
  - Pyrimidines: 510
    - ADW 742: 1

Experts

1.	Campos, Maria: 1 article (06/2006)
2.	Hernández, Teresa: 1 article (06/2006)
3.	Mackintosh, Carlos: 1 article (06/2006)
4.	Martins, Ana S: 1 article (06/2006)
5.	Martín, David Herrero: 1 article (06/2006)
6.	Ordóñez, Jose-Luis: 1 article (06/2006)
7.	de Alava, Enrique: 1 article (06/2006)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2006 - "Combination of ADW742 with imatinib, vincristine, and doxorubicin induces a significant reduction of tumor cell growth, mainly by the increase in apoptosis with a pattern depending on IGF1R activation levels. "
2.	Ewing Sarcoma (Sarcoma, Ewing) 06/01/2006 - "Inhibition of Ewing tumor cell proliferation by ADW742 is mediated through blockade of IGF1R signaling. " 06/01/2006 - "This study supports a potential role for ADW742 in the treatment of Ewing tumor and AKT/mTOR as a possible surrogate marker of response to therapy." 06/01/2006 - "We analyzed IGF1R blockade by ADW742, a small molecule specific for this receptor, alone and in combination with imatinib, vincristine, and doxorubicin on Ewing tumor cell lines. " 06/01/2006 - "Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor."

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Doxorubicin (Adriamycin)
3.	Imatinib Mesylate (Gleevec)
4.	Biomarkers (Surrogate Marker)
5.	IGF Type 1 Receptor (IGF 1 Receptor)

Related Therapies and Procedures

1.	Therapeutics